SCHEMBL3757510

SCHEMBL3757510

CCOC(=O)CNC(=O)c1c(O)c(-c2ccco2)cc2nccnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.50
ADORA3 P0DMS8 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
KDM4E B2RXH2 6/20 0.41
MAPT P10636 4/20 0.41
POLB P06746 3/20 0.41
TRIM24 O15164 1/20 0.41
TRIM33 Q9UPN9 1/20 0.41
TDP1 Q9NUW8 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 6/20 0.40
GAA P10253 2/20 0.40
ATM Q13315 1/20 0.40
PTPN7 P35236 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522129 0.86 EGLN3 (0.67) EGLN3KDM4EALDH1A1GAAHPGD
SCHEMBL3528513 0.85 EGLN3 (0.46) EGLN3ADORA3ADORA2AADORA1KDM4E
SCHEMBL3521075 0.85 EGLN3 (0.52) EGLN3KDM4EMAPTALDH1A1GAA
SCHEMBL3520565 0.82 EGLN3 (0.50) EGLN3KDM4EMAPTPOLBTDP1
SCHEMBL3520286 0.80 EGLN3 (0.57) EGLN3KDM4EMAPTALDH1A1GAA
SCHEMBL3519693 0.80 EGLN3 (0.54) EGLN3KDM4EMAPTALDH1A1GAA
SCHEMBL3756337 0.79 EGLN3 (0.43) EGLN3KDM4EMAPTPOLBALDH1A1
SCHEMBL3519421 0.79 EGLN3 (0.47) EGLN3KDM4EMAPTALDH1A1GAA
SCHEMBL3543886 0.79 EGLN3 (0.48) EGLN3KDM4EMAPTALDH1A1GAA
SCHEMBL3521107 0.79 EGLN3 (0.44) EGLN3KDM4EMAPTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885ADORA3 3353/4885ADORA2A 3714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.